Back to discover
Drug

Etoricoxib

Regulatory activity · MHRA
Emerging researchLate-stage development

Also known as 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-(methylsulfonyl)phenyl)pyridine, 5-chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine, Etoricoxibum.

RxNorm307296ChEMBLCHEMBL416146UNIIWRX4NFY03R
2
Research papers
4
Active clinical trials
2
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time: A Multicenter, Randomized, Parallel-Controlled Study

Clinical trial2026-06-22Results expected Q3 2027 · ClinicalTrials.gov

Clinical Study to Evaluate Safety and Efficacy of Etoricoxib in Patients With Parkinson's Disease Treated With Conventional Treatment

Clinical trial2026-04-08Results expected Q4 2027 · ClinicalTrials.gov

Efficacy and Safety of the Fixed-Dose Combination of Etoricoxib / Tizanidine Versus Etoricoxib in the Treatment of Patients With Acute Low Back Pain Associated to Muscle Spasm

Clinical trial2025-12-01Completed · ClinicalTrials.gov

Efficacy and Safety Study of the Etoricoxib/Betamethasone Combination Compared With Etoricoxib for the Treatment of Patients Diagnosed With an Acute Episode of Bursitis, Tendinitis, or Synovitis of the Shoulder, Elbow, Knee, or Ankle

Clinical trial2025-11-19Completed · ClinicalTrials.gov

Efficacy of Selective COX-2 Inhibitors in Relieving Orthodontic Pain ;a Randomized Controlled Trial

Clinical trial2025-08-18Primary completion · ClinicalTrials.gov

Efficacy and Safety Study for the Combination of Etoricoxib / Betamethasone Compared to Etoricoxib for the Treatment of Patients Diagnosed With Acute Gout Arthritis

Clinical trial2025-04-03Results expected Q4 2026 · ClinicalTrials.gov

The Effect of Low Dose Pregabalin and Etoricoxib Combination on Pain in Comparison to Etoricoxib Alone in Patients Suffering From Chronic Low Back Pain

Clinical trial2024-10-31Primary completion · ClinicalTrials.gov

Efficacy and Safety of the Fixed-Dose Combination of Etoricoxib/Cyanocobalamin Versus Etoricoxib in the Treatment of Patients with Acute Low Back Pain

Clinical trial2024-10-11Completed · ClinicalTrials.gov

Drug Safety Update: Etoricoxib (Arcoxia): revised dose recommendation for rheumatoid arthritis and ankylosing spondylitis

Regulatory2016-10-17MHRA

Drug Safety Update: Etoricoxib: prescribing to patients with high blood pressure

Regulatory2014-12-11MHRA

Further assessment of the clinically effective dose range of etoricoxib: a randomized, double-blinded, placebo-controlled trial in rheumatoid arthritis.

Research2011-09-12Current medical research and opinion

Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial.

Research2010-05-01International journal of rheumatic diseases

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Etoricoxib
Aliases & brands
5-chloro-2-(6-methylpyridin-3-yl)-3-(4-(methylsulfonyl)phenyl)pyridine5-chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridineEtoricoxibum
RxNorm CUI
307296
ChEMBL ID
CHEMBL416146
UNII
WRX4NFY03R
Regulatory jurisdictions
mhra

Regulatory timeline

2 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Authorities
MHRA
Total events
2
mhraMedicines and Healthcare products Regulatory Agency· 2 events
2016-10-17Safety communicationSafety
Drug Safety Update: Etoricoxib (Arcoxia): revised dose recommendation for rheumatoid arthritis and ankylosing spondylitis
Evidence ↗
2014-12-11Safety communicationSafety
Drug Safety Update: Etoricoxib: prescribing to patients with high blood pressure
Evidence ↗

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).

Clinical trials

66 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
66
registered trials across all phases
LATEST COMPLETION 2025
4
Active studies
3
Recruiting
51
Late-stage (III+)
46
Completed
16
Discontinued
PHASE DISTRIBUTIONn = 66
Early Phase 11Phase 15Phase 29Phase 318Phase 425Phase N / A8

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time: A Multicenter, Randomized, Parallel-Controlled Study

Not yet recruitingPH IVFirst Affiliated Hospital of Wenzhou Medical Universityn=1422027

The Effect of Low Dose Pregabalin and Etoricoxib Combination on Pain in Comparison to Etoricoxib Alone in Patients Suffering From Chronic Low Back Pain

Unknown statusPH IVMuhammad Ilyasn=1402024

Preemptive Use of Etoricoxib and Dexamethasone: Effect on Early Bone Healing, Inflammatory Response, and Postoperative Parameters After Impacted Lower Third Molar Surgery

CompletedPH IVUniversity of Belgraden=902022

Effect of Continuous Administration of Different Therapeutic Dosages of Indomethacin and Etoricoxib in the Management of Axial Spondyloarthritis: A Randomized Controlled Trial

CompletedPH IVBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladeshn=642016

The Central Nervous Penetration of Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Reaction in Patients Undergoing Hip Arthroplasty

CompletedPH IVKuopio University Hospitaln=242014

Recent completions

Trials that read out recently, adding to the completed evidence base.

Efficacy and Safety of the Fixed-Dose Combination of Etoricoxib / Tizanidine Versus Etoricoxib in the Treatment of Patients With Acute Low Back Pain Associated to Muscle Spasm

CompletedPH IIILaboratorios Silanes S.A. de C.V.n=1362025

Efficacy and Safety Study of the Etoricoxib/Betamethasone Combination Compared With Etoricoxib for the Treatment of Patients Diagnosed With an Acute Episode of Bursitis, Tendinitis, or Synovitis of the Shoulder, Elbow, Knee, or Ankle

CompletedPH IIILaboratorios Silanes S.A. de C.V.n=892025

Efficacy and Safety of the Fixed-Dose Combination of Etoricoxib/Cyanocobalamin Versus Etoricoxib in the Treatment of Patients with Acute Low Back Pain

CompletedPH IIILaboratorios Silanes S.A. de C.V.n=1902024

Biomarkers for Prediction of Analgesic Efficacy Based on Interrelations Between Pain Modulation and EEG vs. Drugs' Mode of Action in Knee OA

CompletedN/ARambam Health Care Campusn=172024

Immediate Analgesic Effects of Cheek Acupuncture for Acute Gouty Arthritis

CompletedN/AGuangdong Provincial Hospital of Traditional Chinese Medicinen=762023

Preemptive Use of Etoricoxib and Dexamethasone: Effect on Early Bone Healing, Inflammatory Response, and Postoperative Parameters After Impacted Lower Third Molar Surgery

CompletedPH IVUniversity of Belgraden=902022

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20102011
Journals, researchers & institutions
Top journals
  • Current medical research and opinion1
  • International journal of rheumatic diseases1
Leading researchers
  • Boice JA1
  • Chen MH1
  • Chen WJ1
  • Cheng TT1
  • Curtis SP1
  • Frontera N1
  • Gammaitoni AR1
  • Greenwald M1
Leading institutions
free-text, unnormalised
  • Taipei Veterans General Hospital1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.